

## Dual PI3K/mTOR Inhibition Induces Structural Changes in Tumor Vasculature Assessed by Vessel Size Imaging

S. K. Wyatt<sup>1</sup>, S. E. Ungersma<sup>1</sup>, J. R. Oeh<sup>2</sup>, C. Ho<sup>1</sup>, T. C. Cao<sup>1</sup>, H. Koepfen<sup>3</sup>, L. S. Friedman<sup>2</sup>, D. Sampath<sup>2</sup>, and R. A. Carano<sup>1</sup>

<sup>1</sup>Biomedical Imaging, Genentech, Inc, South San Francisco, CA, United States, <sup>2</sup>Translational Oncology, Genentech, Inc, South San Francisco, CA, United States, <sup>3</sup>Pathology, Genentech, Inc, South San Francisco, CA, United States

**Objectives.** Previous studies have reported a reduction in the dynamic contrast enhanced magnetic resonance imaging (MRI) parameter  $K^{trans}$  following treatment with a dual PI3K/mTOR inhibitor (PI3K/mTORi) [1]. These  $K^{trans}$  changes were attributed to an inhibition of vascular endothelial growth factor signaling through PI3K, leading to a suppression of eNOS-induced vascular permeability and vasodilation [1]. However, the effects of PI3K/mTORi on vascular structure remain unknown. This study aims to elucidate the role of PI3K and mTOR inhibition on vascular structure using an *in-vivo* multispectral vessel size index (VSI) MRI approach and *ex-vivo* micro-computed tomography ( $\mu$ CT) angiography.


**Methods. Animal Model.** Animal procedures were approved by the institutional AAALAC-accredited review board. Two cohorts of athymic nude mice were inoculated subcutaneously on the hind limb with  $3.5 \times 10^6$  HM7 (human colorectal cancer) cells for the independent VSI and  $\mu$ CT studies.

**Multispectral VSI MRI:** MRI was performed on a 4.7T Varian Unity Inova MRI system with a Varian 20mm two-loop surface coil. Eight coronal, 1-mm-thick slices were acquired with a  $25.6 \times 25.6$ mm FOV and  $64 \times 64$  (ADC,  $T_2$ ) or  $128 \times 128$  ( $T_2^*$ ) matrix. A multi-slice, diffusion-weighted fast spin-echo imaging sequence was used to obtain ADC measurements (6 b-values from 82-1129  $s/mm^2$ , TR=3s, ETL=4, NEX=2,  $\delta=3.3$ ms,  $\Delta=30$ ms).  $T_2$  and  $M_0$  maps were acquired using a multi-slice, spin-echo imaging sequence (sems, TE=5,26,47,68 ms, TR=3s and NEX=1) and  $T_2^*$  maps were acquired using a multi-slice gradient echo sequence (mgems, TE=5,10,15,20,25,30,35,40ms, TR=345ms and NEX=4). Subsequently, a USPIO contrast agent (200 $\mu$ mol/kg, Molday ION, BioPAL) was delivered via tail-vein catheter and post-contrast sems and mgems sequences were repeated to calculate  $T_2$  and  $T_2^*$  maps, respectively. Multispectral VSI MRI parameters including vessel density (Q), VSI, and fractional blood volume were calculated voxel-by-voxel in the viable tumor tissue using the ADC map and the pre- and post-contrast  $T_2$  and  $T_2^*$  maps in a multispectral approach [2,3].  **$\mu$ CT angiography:** Upon sacrifice, mice were perfused with lead chromate latex MICROFIL (Flowtech). *Ex-vivo* tumors were imaged on a SCANCO Medical  $\mu$ CT 40 system (45kV, 177 $\mu$ A, 450ms, 16 $\mu$ m isotropic voxels). The vascular network and tumor volume were automatically extracted from the images [4] and vascular density was calculated as vascular volume/tumor volume. **Experimental details:** VSI MRI was performed pre- and 24h post-tx with 10mg/kg GDC-0980 (n=9) or methylcellulose/Tween-80 (MCT vehicle control, n=9). *Ex-vivo*  $\mu$ CT was performed in a 2nd cohort of mice 24h post-tx with 10mg/kg GDC-0980 (n=10) or MCT (n=10).


**Results.** Inhibition of the PI3K and mTOR pathways resulted in significant growth suppression of viable tumor tissue as well as changes in vascular structure as demonstrated by *in-vivo* multispectral VSI MRI (Fig 1,2) and confirmed by the independent *ex-vivo*  $\mu$ CT angiography study (Fig 3). More specifically, vehicle-treated viable tumor tissue grew an average of  $34 \pm 17 mm^3$  in 24h ( $p < 0.0005$  vs baseline), while PI3K/mTORi-treated viable tumor volume remained static ( $-7 \pm 21 mm^3$ ,  $p < 0.0005$  vs control, Fig 1a). Structurally, a single dose of the dual PI3K/mTORi reduced the VSI-derived Q by 39% in 24h ( $-0.0020 \pm 0.00060 ms^{-1/3}$ ,  $p < 0.0001$  vs baseline, Fig 1b,2), which was significantly reduced relative to the changes observed in the vehicle-treated tumors ( $-0.00084 \pm 0.00051 ms^{-1/3}$ ,  $p < 0.0005$  vs PI3K/mTORi, Fig 1b,2). This result is further corroborated by the *ex-vivo*  $\mu$ CT data demonstrating a -54% difference between control- and PI3K/mTORi-treated vascular density 24h post-treatment (Control:  $0.026 \pm 0.0063$ , PI3K/mTORi:  $0.057 \pm 0.014$ ,  $p < 0.0001$ , Fig 3). In addition, PI3K/mTORi significantly increased the VSI by  $13 \pm 9.1 \mu m$  in 24h ( $p < 0.005$  vs baseline and  $p < 0.01$  vs control, Fig 1c) and decreased the fractional blood volume by  $-0.014 \pm 0.0054$  ( $p < 0.0001$  vs baseline and  $p < 0.05$  vs control, Fig 1d), consistent with the loss of small vessels.

**Discussion.** Overall, we have demonstrated the ability of multispectral VSI MRI to detect vascular structural changes *in vivo* in response to dual PI3K/mTORi, which are consistent with those observed by *ex-vivo*  $\mu$ CT angiography. Furthermore, these results help elucidate the currently unknown effects of inhibiting the PI3K and mTOR pathways on vascular structure.


[1] Schnell *et al.*, Cancer Res. 2008: 6598-6607. [2] Berry *et al.*, MRM. 2008: 64-72. [3] Ungersma *et al.*, MRM. 2010: 1637-1647. [4] Shojaei F *et al.* Nature 2007; 450: 825-831.



**Fig 1.** Change in (a) viable tumor tissue, (b) Q, (c) VSI, (d) fractional blood volume 24h post-tx (avg $\pm$  SEM). \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.0005$  t-test vs control. #  $p < 0.05$ , ##  $p < 0.005$ , ###  $p < 0.0005$ , ####  $p < 0.0001$  in paired t-test vs pre-tx.



**Fig 2.** Representative viable tumor Q maps overlaid onto their corresponding  $M_0$  images pre-tx and 24h post-tx with MCT or PI3K/mTORi.



**Fig 3.** (a) Representative volumetric  $\mu$ CT-angio renderings 24h post-tx with MCT or PI3K/mTORi. (b) Mean vascular density 24h post-treatment with MCT or PI3K/mTORi (avg $\pm$  SEM).